Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.18553/jmcp.2020.20166 http://scihub22266oqcxt.onion/10.18553/jmcp.2020.20166 32329404!10391148!32329404     free     free     free Deprecated: Implicit conversion from float 209.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 209.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 209.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 209.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       J+Manag+Care+Spec+Pharm 2020 ; 26 (8): 952-955 Nephropedia Template TP {{tp|p=32329404|t=2020. Pharmacy s Call for Authorities to Aggressively Enforce Laws Addressing Price Gouging |pdf=|usr=}}{{32329404}} gab.com Text Pharmacy s Call for Authorities to Aggressively Enforce Laws Addressing Price Gouging JO: J Manag Care Spec Pharm http://www.kidney.de/pget.php?&tw=1&pmid=32329404 #FOAvip Early reports of potential treatment for coronavirus disease (COVID-19) have raised concerns related to pharmaceutical distribution. Despite the lack of high-quality evidence, the mere hope of effectiveness of potential treatments, such as hydroxychloroquine, has led to surges in demand for these products, and many pharmacists are already informally reporting shortages through social channels. As manufacturers and wholesale distributors struggle to fulfill orders for drugs such as hydroxychloroquine, short-term price increases may seem reasonable in a free market when demand increases. However, any price increases by manufacturers, wholesale distributors, and pharmacies might be seen as exploitive gouging of consumers during a declared emergency. In addition to concerns of price gouging, increases in prescription drug utilization during the pandemic may lead to increases in spending for all payers as members may be treated for COVID-19. This article explores pharmaceutical supply chain and drug pricing nuances that may cause problems for payers and pharmacies as the country battles this global pandemic. DISCLOSURES: No funding supported the writing of this article. Mattingly reports unrelated consulting fees from the National Health Council, Bristol Myers Squibb, G&W Laboratories, Allergy and Asthma Foundation of American, and the Massachusetts Health Policy Commission. Hogue has nothing to disclose. Twit Text FOAVip Pharmacy s Call for Authorities to Aggressively Enforce Laws Addressing Price Gouging ????J Manag Care Spec Pharm http://www.kidney.de/pget.php?&tw=1&pmid=32329404 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=32329404 #FOAvip English Wikipedia <ref>{{Cite pmid|32329404}}</ref> Pharmacy s Call for Authorities to Aggressively Enforce Laws Addressing Price Gouging #MMPMID32329404 Mattingly TJ 2nd; Hogue MD J Manag Care Spec Pharm 2020[Aug]; 26 (8): 952-955 PMID32329404show ga Early reports of potential treatment for coronavirus disease (COVID-19) have raised concerns related to pharmaceutical distribution. Despite the lack of high-quality evidence, the mere hope of effectiveness of potential treatments, such as hydroxychloroquine, has led to surges in demand for these products, and many pharmacists are already informally reporting shortages through social channels. As manufacturers and wholesale distributors struggle to fulfill orders for drugs such as hydroxychloroquine, short-term price increases may seem reasonable in a free market when demand increases. However, any price increases by manufacturers, wholesale distributors, and pharmacies might be seen as exploitive gouging of consumers during a declared emergency. In addition to concerns of price gouging, increases in prescription drug utilization during the pandemic may lead to increases in spending for all payers as members may be treated for COVID-19. This article explores pharmaceutical supply chain and drug pricing nuances that may cause problems for payers and pharmacies as the country battles this global pandemic. DISCLOSURES: No funding supported the writing of this article. Mattingly reports unrelated consulting fees from the National Health Council, Bristol Myers Squibb, G&W Laboratories, Allergy and Asthma Foundation of American, and the Massachusetts Health Policy Commission. Hogue has nothing to disclose. |*Coronavirus Infections[MESH] |*Pandemics[MESH] |*Pneumonia, Viral[MESH] |COVID-19[MESH] |Drug Costs/*ethics[MESH] |Ethics, Pharmacy[MESH] |Health Policy[MESH] |Humans[MESH] |Pharmaceutical Preparations/*supply & distribution[MESH] |Pharmaceutical Services[MESH] |Pharmacy/*trends[MESH]Pharmacy s Call for Authorities to Aggressively Enforce Laws Addressin(epmc).pdf DeepDyve Pubget Overpricing